Tumours with NTRK gene fusion produce an altered TRK protein ... cells and slow the worsening of the disease. TRK fusion cancer can occur in any part of the body, including the lungs, thyroid, colon, ...

The US regulator says Retevmo (selpercatinib, formerly LOXO-292) can be used to treat lung and thyroid cancers with a mutation or fusion in the RET gene, specifically non-small cell lung cancer ...

NTRK fusion cancer is rare, affecting no more than a ... and is more common in sarcomas, brain, kidney and thyroid cancers. Use of the drug will depend on patients receiving genetic testing ...

Through the integration of these novel models, our research seeks to advance our understanding of NTRK fusion-driven cancer biology and to improve therapeutic strategies for these cancers. References: ...

Full approval of Vitrakvi was based on results from three clinical trials in patients with unresectable or metastatic NTRK fusion-positive solid tumors. “This first full approval of an NTRK inhibitor ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types ...

“We are proud to deliver on our promise for patients with this significant step forward, providing a treatment option for pediatric and adult patients living with NTRK gene fusion-positive cancers." ...

NTRK fusion genes occur in various types of adult and pediatric tumors. In some rare tumors, such as salivary gland carcinoma, secretory breast cancer, and infantile fibrosarcoma, the incidence of ...